Mavacamten
- Generic Name
- Mavacamten
- Brand Names
- Camzyos
- Drug Type
- Small Molecule
- Chemical Formula
- C15H19N3O2
- CAS Number
- 1642288-47-8
- Unique Ingredient Identifier
- QX45B99R3J
- Background
Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.
- Indication
Mavacamten is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms by the FDA, Health Canada, and the EMA.
- Associated Conditions
- Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Associated Therapies
- -
Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 13
- Registration Number
- NCT03496168
- Locations
- 🇺🇸
Local Institution - 0003, Scottsdale, Arizona, United States
🇺🇸Local Institution - 0001, New Haven, Connecticut, United States
🇺🇸Local Institution - 0004, Durham, North Carolina, United States
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Conditions
- Obstructive Hypertrophic Cardiomyopathy
- Interventions
- Drug: PlaceboDrug: mavacamten
- First Posted Date
- 2018-03-20
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- MyoKardia, Inc.
- Target Recruit Count
- 251
- Registration Number
- NCT03470545
- Locations
- 🇺🇸
Cedars-Sinai Medical Center (Smidt Heart Institute), Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Houston Methodist Hospital, Houston, Texas, United States
A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
- Conditions
- Non-obstructive Hypertrophic Cardiomyopathy
- Interventions
- Drug: mavacamtenDrug: Placebo
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- MyoKardia, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT03442764
- Locations
- 🇺🇸
The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
🇺🇸UPMC Presbyterian, Pittsburgh, Pennsylvania, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.